Is the Food and Drug Administration killing personalized medicine?

ucm

The Food and Drug Administration’s move to tighten the regulatory screws on personal genomics company 23andMe has ignited a fierce debate between those who believe government oversight of medical data should be increased and techno-libertarians who worry government intervention could squelch innovation.

It’s no surprise where Reason magazine falls in this debate. Editor-in-chief Nick Gillespie interviews Peter Huber, a senior fellow at the Manhattan Institute and author of the recently published The Cure in the Code: How 20th Century Law is Undermining 21st Century Medicineto discuss whether the

Peter Huber. Via Reason.
Peter Huber. Via Reason.

FDA’s aggressive actions will inhibit the next era of medical intervention and drug development, limiting pharmaceutical companies from bringing the advantages of personal genomics to patients quickly and efficiently.

“The search for one-dimensional, very simple correlations—one drug, one clinical effect in all patients—is horrendously obsolete,” says Huber.  Scientists today have the technology to tailor treatments to an individual’s unique genetic code, but the FDA’s outdated “one-size-fits-all” drug approval model is blocking innovation.

Until recent advances in personal genomics and molecular chemistry allowed researchers to see the human body at a molecular level, developing drugs was akin to “one hand clapping”—scientists could control the drug’s chemistry to affect clinical symptoms in patients, but they could not see what the drugs were doing on a molecular level. Every person’s body chemistry is unique, even if two people with a disease have identical clinical symptoms. An understanding of personal genomics can lead to narrowly targeted treatments for individuals.

Regulatory processes within the FDA are choking pharmaceutical efforts to bring the benefits of personal genomics directly to patients, Huber contends. Pharmaceutical companies are very good at designing targeted drugs. The technology—and talent—exists to tease out complex patterns from the enormous amount of molecular and clinical data needed to develop those drugs. However, the FDA does not have the expertise nor the resources that are found among companies like Google or Microsoft, which regularly work with big data. The FDA is still locked into the traditional model of ‘one drug, one clinical effect for all patients.’ Diseases are not ‘one cause, one effect,’ says Huber, and “if you demand that drugs perform that way, we will not cure many of the serious diseases we’re now facing.”

Read the full, original story here: How The FDA is Killing Molecular Medicine: Q/A w Peter Huber

Additional Resources:

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Video: Test everyone – Slovakia goes its own way to control COVID

Video: Test everyone – Slovakia goes its own way to control COVID

As Europe sees record coronavirus cases and deaths, Slovakia is testing its entire adult population. WSJ's Drew Hinshaw explains how ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend